For the Inventor, By the Inventor

Enter assignee name

Basel, Switzerland

Novartis Ag

USPTO Granted Patents = 3,923

CIPO Patents = 1,941

EPO Patents = 1,862

Trademarks = 1,799

Forward Citations = 36,536

Loading Chart...

Loading Chart...

7,585 inventors (with patents filed for the assignee):

Pascal Furet (83 out of 97 patents)

Paul William Manley (60 out of 63 patents)

Frank Chang (59 out of 91 patents)

4. Yongxing Qiu (51 out of 78 patents)

5. Robin Alec Fairhurst (50 out of 50 patents)

6. Lynn Cook Winterton (50 out of 72 patents)

7. Guido Bold (42 out of 62 patents)

8. Robert Mah (41 out of 48 patents)

9. Roger Biel (40 out of 54 patents)

10. John Martin Lally (39 out of 41 patents)

11. Jennifer Brogdon (37 out of 37 patents)

12. John Dallas Pruitt (36 out of 69 patents)

13. Robert Carey Tucker (36 out of 52 patents)

14. Peter Hagmann (36 out of 48 patents)

15. Andreas Loew (35 out of 47 patents)

Core Competencies:

Quinoline Compounds

Aminopyridine Derivatives

Bispecific Antibodies

Bruton's Tyrosine Kinase Inhibitors

NLRP3 Inflammasome Inhibitors

Chimeric Antigen Receptors

NMDA Receptor Modulators

Antiviral Compounds

Sustained Release Delivery Systems

CD19 Chimeric Antigen Receptors

Urea Compounds

Hepatitis B Antibodies

3,923 patents: Sort by Forward Citations

1. 12473273 - Quinoline compounds and compositions for inhibiting EZH2 (2025-11-18),

2. 12466808 - Aminopyridine derivatives and their use as selective ALK-2 inhibitors (2025-11-11),

3. 12453726 - Methods of using factor B inhibitors (2025-10-28),

4. 12441786 - Bispecific antibodies for use in treatment of NLRC4-GOF inflammasomapathy (2025-10-14),

5. 12441737 - Manufacture of compounds and compositions for inhibiting the activity of SHP2 (2025-10-14),

6. 12441733 - Substituted 2,4-dioxotetrahydropyrimidines as intermediates in the synthesis of bruton's tyrosine kinase inhibitors (2025-10-14),

7. 12435150 - Anti-CD40 antibodies for use in treatment of hidradenitis suppurativa (2025-10-07),

8. 12433949 - Sustained release delivery systems comprising traceless linkers (2025-10-07),

9. 12421223 - Compounds and compositions for treating conditions associated with NLRP activity (2025-09-23),

10. 12419894 - Ribociclib tablet (2025-09-23),

11. 12419889 - Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor (2025-09-23),

12. D1092724 - Medical autoinjector device (2025-09-09),

13. 12410255 - Natriuretic peptide receptor 1 antibodies and methods of use (2025-09-09),

14. 12404261 - Compounds and compositions for treating conditions associated with cGAS (2025-09-02),

15. 12390468 - Crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide (2025-08-19),

Novartis AG is a multinational pharmaceutical company based in Switzerland. They research, develop, manufacture, and market a wide range of healthcare products, including prescription drugs, generic drugs, vaccines, over-the-counter drugs, and animal health products. Novartis aims to improve global health by providing innovative treatments for various diseases and conditions. Their commitment to research and development has led to breakthroughs in areas such as oncology, cardiovascular health, ophthalmology, immunology, and neuroscience.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

3,923 Patents

#1 in Basel

#1 in Switzerland

#230 in the World

Basel, Switzerland

Novartis Ag

Forward Citations = 36,536

7,585 inventors:

Pascal Furet (83 out of 97 patents)

Paul William Manley (60 out of 63 patents)

Frank Chang (59 out of 91 patents)

4. Yongxing Qiu (51 out of 78 patents)

5. Robin Alec Fairhurst (50 out of 50 patents)

Please report any incorrect information to support@idiyas.com

Loading…